Patricia Katz1,2, George J Wan3, Paola Daly4, Lauren Topf4, Erin Connolly-Strong3,5, Ryan Bostic6, Michael L Reed6. 1. School of Medicine, University of California San Francisco, San Francisco, CA, USA. Patti.Katz@ucsf.edu. 2. Arthritis Research Group, University of California San Francisco, 3333 California Street, San Francisco, CA, 94143-0936, USA. Patti.Katz@ucsf.edu. 3. Global Head of Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA. 4. The Lupus Foundation of America, Washington, DC, USA. 5. Field Medical Affairs, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA. 6. Vedanta Research, Chapel Hill, NC, USA.
Abstract
PURPOSE: To understand the influence of the systemic lupus erythematosus (SLE)-related flares on patient's health-related quality of life (HRQoL). METHODS: An online survey included individuals with self-reported physician's diagnosis of SLE or lupus nephritis (LN). Lupus impact tracker (LIT) assessed lupus symptoms and HRQoL, SLE-Family questionnaire measured family role functioning, and Healthy Days Core Module (HDCM) measured overall mental and physical health. Chi-square and analysis of variance evaluated differences by flare frequency. Multivariable linear regression and generalized linear models evaluated the independent relationships of flare frequency to HRQoL. RESULTS: 1066 respondents with SLE or LN completed the survey. Mean (SD) duration of illness was 12.4 (10.1) years. 93.4% (n = 996) were women, 82.3% (n = 830) were White, and 49.7% (n = 530) were employed or students. More frequent flares were associated with significantly worse scores on all HRQoL measures: LIT (adjusted means: 0 flares, 31.8; 1-3 flares, 47.0; 4-6 flares, 56.1; ≥ 7 flares, 63.6; P < 0.001); SLE-Family (adjusted means: 0 flares, 3.1; 1-3 flares 3.8; 4-6 flares, 4.3; ≥ 7 flares, 4.6, P < 0.001); HDCM unhealthy days (0 flares, 8.7; 1-3 flares, 17.4; 4-6 flares, 21.5; ≥ 7 flares, 26.2 days, P < 0.001). CONCLUSION: Lupus flares contributed to impaired functional and psychological well-being, family functioning, and number of monthly healthy days. Better understanding of the burden of flare activity from the patient's perspective will support a holistic approach to lupus management.
PURPOSE: To understand the influence of the systemic lupus erythematosus (SLE)-related flares on patient's health-related quality of life (HRQoL). METHODS: An online survey included individuals with self-reported physician's diagnosis of SLE or lupus nephritis (LN). Lupus impact tracker (LIT) assessed lupus symptoms and HRQoL, SLE-Family questionnaire measured family role functioning, and Healthy Days Core Module (HDCM) measured overall mental and physical health. Chi-square and analysis of variance evaluated differences by flare frequency. Multivariable linear regression and generalized linear models evaluated the independent relationships of flare frequency to HRQoL. RESULTS: 1066 respondents with SLE or LN completed the survey. Mean (SD) duration of illness was 12.4 (10.1) years. 93.4% (n = 996) were women, 82.3% (n = 830) were White, and 49.7% (n = 530) were employed or students. More frequent flares were associated with significantly worse scores on all HRQoL measures: LIT (adjusted means: 0 flares, 31.8; 1-3 flares, 47.0; 4-6 flares, 56.1; ≥ 7 flares, 63.6; P < 0.001); SLE-Family (adjusted means: 0 flares, 3.1; 1-3 flares 3.8; 4-6 flares, 4.3; ≥ 7 flares, 4.6, P < 0.001); HDCM unhealthy days (0 flares, 8.7; 1-3 flares, 17.4; 4-6 flares, 21.5; ≥ 7 flares, 26.2 days, P < 0.001). CONCLUSION: Lupus flares contributed to impaired functional and psychological well-being, family functioning, and number of monthly healthy days. Better understanding of the burden of flare activity from the patient's perspective will support a holistic approach to lupus management.
Entities:
Keywords:
Disease activity; Flare; Quality of life; Role functioning; Systemic lupus erythematosus
Authors: Elena Castellano-Rioja; María Del Carmen Giménez-Espert; Ana Soto-Rubio Journal: Int J Environ Res Public Health Date: 2020-11-20 Impact factor: 3.390
Authors: Fhabián S Carrión-Nessi; María V Marcano-Rojas; Sinibaldo R Romero Arocha; Daniela L Mendoza Millán; David A Forero-Peña; Allen W Antuarez-Magallanes; Soham Al Snih; Martín A Rodríguez; Yurilís J Fuentes-Silva Journal: BMC Rheumatol Date: 2022-01-04
Authors: Medha Barbhaiya; Jonah M Levine; Caroline H Siegel; Vivian P Bykerk; Deanna Jannat-Khah; Lisa A Mandl Journal: Clin Rheumatol Date: 2021-10-30 Impact factor: 3.650
Authors: Manuel Francisco Ugarte-Gil; Rocio Violeta Gamboa-Cardenas; Cristina Reátegui-Sokolova; Victor Román Pimentel-Quiroz; Mariela Medina; Claudia Elera-Fitzcarrald; Francisco Zevallos; Cesar Augusto Pastor-Asurza; Federico Zazzetti; Chetan S Karyekar; Graciela S Alarcón; Risto Alfredo Perich-Campos Journal: Lupus Sci Med Date: 2022-03
Authors: Richard Furie; Eric F Morand; Ian N Bruce; David Isenberg; Ronald van Vollenhoven; Gabriel Abreu; Lilia Pineda; Raj Tummala Journal: Arthritis Rheumatol Date: 2021-09-22 Impact factor: 10.995